Protein therapeutics is artificially synthesized protein on large scale through genetically modified host cells that is used in treatment of chronic diseases such as cancer, diabetes and CVD. According to IMS Health Market Prognosis, the total market size of pharmaceutical industry was approximately $962.1 billion in 2012. This shows growth opportunities for protein therapeutics market. High efficiency of protein therapeutics with fewer side effects is driving the protein therapeutics market. For example, Approximately 17.7 adults consumed oral medication (Pills or insulin) for diabetes in 2011. Protein therapeutics market growth is hindered by adverse side effects in chronic diseases and cost of production.
In order to overcome the restraints, companies are conducting research for redesigning the protein synthesis structure. For Example, Genetech and Biogen Idec received approval from US FDA for their Rituxab®. The report provides an in-depth intelligence of key developmental strategies adopted by key companies. The report provide intelligence on future expected market trends and their impact on protein therapeutic market through impact analysis.
The key companies included in the report are, Novo Nordisk, Johnson & Johnson, Eli Lilly & Company, Roche, Group Biogen Idec Inc., Sanofi-Aventis, Merck Serono S.A., Amgen Inc., Pfizer, and Abbott Laboratories.
KEY MARKET SEGMENTS
GLOBAL MARKET, BY THERAPEUTIC PROTEINS
GLOBAL MARKET, BY GEOGRAPHIES